I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Hyperuricemia has been found to be associated with cardiovascular disease \[[@ref1][@ref2]\]. Thus, whether lowering serum uric acid can reduce the risk of cardiovascular disease is an important issue. Allopurinol, a uric acid-lowering drug mediated by the pathway of inhibition of xanthine oxidase, is frequently used to treat hyperuricemia \[[@ref3]\]. Moreover, the association between allopurinol use and acute myocardial infarction remains to be controversial. Some studies revealed that allopurinol use could reduce the risk of acute myocardial infarction \[[@ref4][@ref5][@ref6][@ref7]\], but another study revealed that allopurinol use could increase the risk \[[@ref8]\]. One study even revealed that allopurinol use should be considered as a contraindication among patients with ischemic heart disease \[[@ref9]\].

Cardiovascular disease was the second leading cause of total death in Taiwan in 2016. Totally, 20,812 deaths were related to cardiovascular disease, accounting for 12.07% of total death in Taiwan in 2016 \[[@ref10]\]. One study in Taiwan revealed that the prevalence rates of hyperuricemia were 39.4% in men and 17.4% in women \[[@ref11]\]. However, there is no definite conclusion about whether allopurinol use can reduce or increase the risk of acute myocardial infarction in older people in Taiwan. If the association can be established, more clinical information can be added to the care of older people. Therefore, we conducted a population-based case--control study to examine the following questions: (1) What association can be found between allopurinol use and acute myocardial infarction? (2) Whether there is a dosage-dependent relationship of allopurinol use on the risk of acute myocardial infarction?

M[ATERIALS AND METHODS]{.smallcaps} {#sec1-2}
===================================

Study design and data source {#sec2-1}
----------------------------

The study design and data source were adapted from previous studies \[[@ref12][@ref13][@ref14]\]. We conducted a population-based case--control study using the 2000--2013 database of the Taiwan National Health Insurance Program. The program began in March 1995 and has covered 99.6% of 23 million people living on an independent country of Taiwan \[[@ref15][@ref16][@ref17]\].

Ethical statement {#sec2-2}
-----------------

The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115). Informed written consent was waived because the study was retrospective data.

Study subjects {#sec2-3}
--------------

Subjects aged 65 years or older with the first incident acute myocardial infarction (based on the International Classification of Diseases, 9^th^ Revision, Clinical Modification \[ICD-9\] code 410) were assigned as cases. The date of subjects being diagnosed with the first incident acute myocardial infarction was defined as the index date. For every one case with acute myocardial infarction, approximately two subjects aged 65 years or older without any type of coronary artery disease (ICD-9 codes 410--414) were assigned as matched controls. Both cases and matched controls were matched with sex, age (every 5 years), and the year of index date \[[Figure 1](#F1){ref-type="fig"}\].

![Flowchart showing selection process of study subjects](TCMJ-31-276-g001){#F1}

Definition of allopurinol exposure {#sec2-4}
----------------------------------

To reduce the biased results, subjects whose final prescriptions of allopurinol were filled ≥6 months before the index date were excluded. Therefore, only those subjects whose final prescriptions of allopurinol were filled \<6 months before the index date could be included. The definition of allopurinol use was adapted from previous studies \[[@ref18][@ref19]\]. Briefly speaking, ever use of allopurinol was defined as subjects who had at least a prescription of allopurinol before index date. Never use of allopurinol was defined as subjects who did not have a prescription of allopurinol before the index date.

Comorbidities studied {#sec2-5}
---------------------

Based on ICD-9 codes, comorbidities were selected as follows: alcohol-related disease (ICD-9 codes 291, 303, 305.00, 305.01, 305.02, 305.03, 571.0--571.3, 790.3, and V11.3), cerebrovascular disease (ICD-9 codes 430--438), chronic kidney disease (ICD-9 codes 581--583, 585--587, and 588.8--588.9), chronic obstructive pulmonary disease (ICD-9 codes 491, 492, 493, and 496), diabetes mellitus (ICD-9 codes 250), hyperlipidemia (ICD-9 codes 272.0, 272.1, 272.2, 272.3, and 272.4), and hypertension (ICD-9 codes 401--405).

Statistical analysis {#sec2-6}
--------------------

First, we compared the distributions of demographic information, allopurinol use, and comorbidities between cases and matched controls using the Chi-square test for categorical variables and the *t*-test for continuous variables. Second, the multivariable logistic regression model was used to estimate the odds ratio (OR) and the 95% confidence interval (CI) for acute myocardial infarction associated with allopurinol use. Third, we conducted an analysis about the risk of acute myocardial infarction associated with average daily dosage of allopurinol use. The average daily dose of allopurinol use was calculated using the total quantity of allopurinol divided by total number of days supplied. The average daily dose was divided into two levels according to the third quartile dose, \<200 mg and ≥200 mg. All analyses were performed using the SAS Statistical Software (version 9.2; SAS Institute, Inc., Cary, NA, USA). The results were considered statistically significant when two-tailed *P* \< 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Basic characteristics of the study population {#sec2-7}
---------------------------------------------

There were 4701 cases with acute myocardial infarction and 9369 matched controls, with similar distributions of sex and age \[[Table 1](#T1){ref-type="table"}\]. The mean ages (standard deviation) were 77.1 (7.2) years in cases and 76.9 (7.2) years in matched controls, without statistical significance (*t*-test, *P* = 0.16). Cases were more likely to have a higher proportion of ever use of allopurinol than matched controls, with statistical significance (6.0% vs. 1.54%, Chi-square test, *P* \< 0.001). Cases had higher proportions of alcohol-related disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, and hypertension than matched controls, with statistical significance (Chi-square test, *P* \< 0.001 for all).

###### 

Characteristics between cases with acute myocardial infarction and matched controls

  Variable                                 Matched controls (*n*=9369), *n* (%)   Cases with acute myocardial infarction (*n*=4701), *n* (%)   *P*\*
  ---------------------------------------- -------------------------------------- ------------------------------------------------------------ ---------
  Sex                                                                                                                                          
   Female                                  3967 (42.3)                            1992 (42.4)                                                  0.97
   Male                                    5402 (57.7)                            2709 (57.6)                                                  
  Age group (years)                                                                                                                            
   65-74                                   3944 (42.0)                            1972 (42.0)                                                  0.90
   75-84                                   4024 (43.0)                            2012 (42.8)                                                  
   ≥85                                     1401 (15.0)                            717 (15.2)                                                   
  Age (years), mean±SD^†^                  76.9±7.2                               77.1±7.2                                                     0.16
  Ever use of allopurinol use              144 (1.5)                              282 (6.0)                                                    \<0.001
  Comorbidities\*                                                                                                                              
   Alcohol-related disease                 216 (2.3)                              163 (3.5)                                                    \<0.001
   Cerebrovascular disease                 812 (8.7)                              1365 (29.0)                                                  \<0.001
   Chronic kidney disease                  566 (6.0)                              944 (20.1)                                                   \<0.001
   Chronic obstructive pulmonary disease   2192 (23.4)                            2023 (43.0)                                                  \<0.001
   Diabetes mellitus                       878 (9.4)                              1543 (32.8)                                                  \<0.001
   Hyperlipidemia                          1566 (16.7)                            1705 (36.3)                                                  \<0.001
   Hypertension                            4697 (50.1)                            4035 (85.8)                                                  \<0.001

Data are presented as the number of subjects in each group with percentages given in parentheses. \*Chi-square test and, ^†^*T*-test comparing subjects with and without acute myocardial infarction. SD: Standard deviation

Risk of acute myocardial infarction associated with allopurinol use {#sec2-8}
-------------------------------------------------------------------

After adjusting for potential covariables, the multivariable logistic regression model revealed that the adjusted OR of acute myocardial infarction was 2.2 (95% CI 1.7--2.7) for subjects with ever use of allopurinol, compared with never use of allopurinol \[[Table 2](#T2){ref-type="table"}\]. In addition, cerebrovascular disease (adjusted OR 2.5, 95% CI 2.2--2.7), chronic kidney disease (adjusted OR 2.0, 95% CI 1.7--2.2), chronic obstructive pulmonary disease (adjusted OR 2.0, 95% CI 1.8--2.1), diabetes mellitus (adjusted OR 2.5, 95% CI 2.3--2.8), hyperlipidemia (adjusted OR 1.6, 95% CI 1.4--1.7), and hypertension (adjusted OR 3.5, 95% CI 3.2--3.8) were associated with acute myocardial infarction.

###### 

Crude and adjusted odds ratio and 95% confidence interval of acute myocardial infarction associated with allopurinol use and comorbidities by logistical regression model

  Variable                                                 Crude   Adjusted^†^         
  -------------------------------------------------------- ------- ------------- ----- ---------
  Sex (male vs. female)                                    1.0     0.9-1.1       \-    \-
  Age (per 1 year)                                         1.0     0.9-1.0       \-    \-
  Ever use of allopurinol use (never use as a reference)   4.1     3.3-5.0       2.2   1.7-2.7
  Comorbidities (yes vs. no)                                                           
   Alcohol-related disease                                 1.5     1.2-1.9       1.2   0.9-1.6
   Cerebrovascular disease                                 4.3     3.9-4.8       2.5   2.2-2.7
   Chronic kidney disease                                  3.9     3.5-4.4       2.0   1.7-2.2
   Chronic obstructive pulmonary disease                   2.5     2.3-2.7       2.0   1.8-2.1
   Diabetes mellitus                                       4.7     4.3-5.2       2.5   2.3-2.8
   Hyperlipidemia                                          2.8     2.6-3.1       1.6   1.4-1.7
   Hypertension                                            6.0     5.5-6.6       3.5   3.2-3.8

^†^Adjustment for alcohol-related disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, and hypertension. OR: Odd ratio, CI: Confidence interval

Risk of acute myocardial infarction associated with average daily dosage of allopurinol use {#sec2-9}
-------------------------------------------------------------------------------------------

We conducted an analysis about the risk of acute myocardial infarction associated with average daily dosage of allopurinol use. The adjusted ORs of acute myocardial infarction were 2.0 (95% CI 1.5--2.6) for subjects with average daily dosage of allopurinol \<200 mg and 2.5 (95% CI 1.6--4.0) for subjects with average daily dosage of allopurinol use ≥200 mg, compared with never use of allopurinol \[[Table 3](#T3){ref-type="table"}\].

###### 

Risk of acute myocardial infarction associated with average daily dosage of allopurinol use

  Variable                                       Case number/control number   Crude OR   95% CI      Adjusted OR^†^   95% CI
  ---------------------------------------------- ---------------------------- ---------- ----------- ---------------- -----------
  Never use of allopurinol as a reference        4419/9225                    1.0        Reference   1.0              Reference
  Average daily dosage of allopurinol use (mg)                                                                        
   \<200                                         228/108                      4.4        3.5-5.6     2.0              1.5-2.6
   ≥200                                          54/36                        3.1        2.1-4.8     2.5              1.6-4.0

^†^Adjustment for alcohol-related disease, cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hyperlipidemia, and hypertension. OR: Odd ratio, CI: Confidence interval

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

To date, there remains to be controversy about the association between allopurinol use and the risk of acute myocardial infarction. Based on the hypothesis that the inhibition of xanthine oxidase might reduce radical oxygen species and vascular oxidative stress, and ameliorate myocardial ischemia \[[@ref20]\], that was why allopurinol, an inhibitor of xanthine oxidase, was proposed to be associated with reduced risk of acute myocardial infarction in previous studies \[[@ref4][@ref5][@ref6][@ref7]\].

In our case--control study, only those subjects whose final prescriptions of allopurinol were filled \<6 months before the index date could be included. Thus, allopurinol use among these subjects could be regarded as current or recent use, rather than the past use, based on the definition of previous studies \[[@ref14][@ref21]\]. We noted that allopurinol use was associated with increased odds of acute myocardial infarction in older people \[adjusted OR 2.15, [Table 2](#T2){ref-type="table"}\]. This finding is partially compatible with a cohort study, revealing that allopurinol use could increase the cardiovascular risk, with a hazard ratio of 1.25 (95% CI 1.10--1.41) \[[@ref8]\]. Although one double-blind study revealed that allopurinol use should be considered as a contraindication among patients with ischemic heart disease \[[@ref9]\], our study was unable to give such a suggestion due to lack of a causal relationship.

We noted that there seemed to be a dosage-dependent relationship of allopurinol use on the risk of acute myocardial infarction. That is, the higher the average daily dosage of allopurinol use, the greater the risk of acute myocardial infarction. This finding is contrary to previous studies, revealing that the higher dose of allopurinol use (300 mg or higher daily) was associated with reduced risk of acute myocardial infarction, with an OR of 0.30 (95% CI 0.13--0.72) \[[@ref5]\].

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

Our population-based case--control study does not support the hypothesis that allopurinol has a cardioprotective effect in older people, but allopurinol use might be associated with increased odds of acute myocardial infarction, particularly at higher dosage.
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